Table 4.
Survival analysis after CAPTEM treatment sorted by Tumor Characteristics.
| Factors | n | Median PFS (95% CI) | p Value (Log-Rank) | Median OS (95% CI) | p Value (Log-Rank) |
|---|---|---|---|---|---|
| All patients | 116 | 13 (11–23) | 38 (32–46) | ||
| Sex | 0.1713 | 0.1166 | |||
| Female | 48 | 25 (10–35) | NR | ||
| Male | 68 | 12 (7–18) | 33 (29–41) | ||
| Primary Site (n = 116) | 0.0083 | 0.5621 | |||
| pNEN | 47 | 29 (12–80) | 35 (29–80) | ||
| Non-pNEN | 69 | 11 (6–18) | 38 (30–46) | ||
| Tumor Differentiation (n = 112) | 0.0192 | 0.0192 | |||
| Well | 94 | 16 (11–26) | 41 (33–46) | ||
| Poor | 18 | 5 (5–12) | 23 (13–25) | ||
| Ki-67 (n = 106) * | 0.0231 | 0.0402 | |||
| Ki-67 < 3% | 24 | 29 (13–39) | NR | ||
| Ki-67 3–20% | 50 | 12 (6–25) | 33 (30–46) | ||
| Ki-67 20–55% | 26 | 7 (3–25) | 33 (14–46) | ||
| Ki-67 > 55% | 6 | 5 (4–12) | 18 (15–25) | ||
* Ki-67 unknown (n = 10). Abbreviation: CAPTEM, capecitabine and temozolomide; PFS, progression free survival; OS, overall survival.